Nextage Therapeutics Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY null	FY null
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.41	0.88	-	0.09	0.19
Revenue Growth (YoY)	-52.85%	-	-	-52.36%	-
Cost of Revenue	0.34	0.65	-	0.08	0.06
Gross Profit	0.08	0.23	-	0.02	0.13
Selling, General & Admin	3.39	3.24	4	5.08	5.61
Research & Development	0.13	0.98	1.85	-	-
Other Operating Expenses	-	-	-	2.06	0.82
Operating Expenses	3.52	4.21	5.85	7.14	6.53
Operating Income	-3.44	-3.99	-5.85	-7.12	-6.4
Interest Expense	-0.03	-0.05	-0.03	-0.16	-0.11
Interest & Investment Income	-	-	0.02	-	-
Earnings From Equity Investments	-	-	0.02	-	-
Currency Exchange Gain (Loss)	0.01	-0.01	-0.16	0.18	-
Other Non Operating Income (Expenses)	-0.01	-0.16	0.01	-0.27	-0.08
EBT Excluding Unusual Items	-3.47	-4.2	-5.99	-7.38	-6.58
Other Unusual Items	-	-	-	-0.56	-9.39
Pretax Income	-3.47	-4.2	-5.99	-7.93	-15.97
Earnings From Continuing Operations	-3.47	-4.2	-5.99	-7.93	-15.97
Minority Interest in Earnings	0.19	0.32	0.4	0.21	-
Net Income	-3.28	-3.88	-5.59	-7.73	-15.97
Net Income to Common	-3.28	-3.88	-5.59	-7.73	-15.97
Shares Outstanding (Basic)	33	29	28	26	11
Shares Outstanding (Diluted)	33	29	28	26	11
Shares Change (YoY)	12.68%	4.79%	6.98%	127.75%	-
EPS (Basic)	-0.10	-0.13	-0.20	-0.30	-1.40
EPS (Diluted)	-0.10	-0.13	-0.20	-0.30	-1.40
Free Cash Flow	-0.8	-2.26	-6.02	-3.97	-6.32
Free Cash Flow Per Share	-0.02	-0.08	-0.22	-0.15	-0.55
Gross Margin	18.40%	25.69%	-	17.58%	69.63%
Operating Margin	-832.69%	-455.14%	-	-7825.28%	-3348.69%
Profit Margin	-794.92%	-442.81%	-	-8492.31%	-8359.16%
Free Cash Flow Margin	-192.49%	-258.22%	-	-4367.03%	-3309.42%
EBITDA	-3.41	-3.96	-5.79	-	-6.3
D&A For EBITDA	0.03	0.03	0.06	-	0.1
EBIT	-3.44	-3.99	-5.85	-7.12	-6.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.